沃森生物(300142.SZ):簽署微生態健康靶向技術獨家再許可協議之修正案
格隆匯7月30日丨沃森生物(300142.SZ)公佈,爲深入貫徹國家“未病先防”慢病防控戰略,進一步拓展“核心菌羣療法”在精準微生態健康和功能性營養幹預領域的研發及商業化應用,增強公司市場競爭力,董事會同意公司與美國NotitiaBiotechnologies Company(以下簡稱“Notitia”)簽署《Amendment to ExclusiveSublicense Agreement》(《獨家再許可協議之修正案》,以下簡稱“修正案”)。根據修正案,Notitia將其與美國新澤西州立羅格斯大學簽署的上遊許可協議所獲得的核心菌羣分析、菌羣靶向移植及營養配方技術授予公司在中國大陸、香港和澳門地區針對非患者人羣進行獨佔開發、製造及商業化的權利。結合既有患者市場授權,本次修正案的簽署標誌着公司將實現“疾病治療幹預”與“慢病防治+大健康營養”雙軌佈局,建立覆蓋院內治療、院外管理及多場景幹預的綜合性健康解決方案。此舉緊密契合國家非藥物幹預、強化慢病營養及慢病防控關口前移政策,通過整合現有臨牀路徑及底層技術平臺建設,以更多元化產品形態覆蓋亞健康及慢病高風險人羣,爲國家慢病綜合防控體系提供新路徑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.